Contribution of thermolabile methylenetetrahydrofolate reductase variant to total plasma homocysteine levels in healthy men and women. Inter99 (2)

Genetic Epidemiology

Volumn 24, Issue 4, 2003, Pages 322-330

  Husemoen, Lise Lotte N ^a   Thomsen, Troels F ^a   Fenger, Mogens ^b   Jørgensen, Henrik L ^b   Jørgensen, Torben ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Age; Heritability; Homocysteine; Interaction; MTHFR C677T polymorphism; Normal ranges; Sex

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE;

ADULT; AGE; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME POLYMORPHISM; FEMALE; GENDER; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGE FACTORS; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; LOGISTIC MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS; SEX CHARACTERISTICS;

EID: 0038754110     PISSN: 07410395     EISSN: None     Source Type: Journal    
DOI: 10.1002/gepi.10239     Document Type: Article

References (45)

1. Altman DG. 1991. Practical statistics for medical research. London: Chapman & Hall.
2. Andersen LB, Vestbo J, Juel K, Bjerg AM, Keiding N, Jensen G, Hein HO, Sorensen TI. 1998. A comparison of mortality rates in three prospective studies from Copenhagen with mortality rates in the central part of the city, and the entire country. Copenhagen Center for Prospective Studies. Eur J Epidemiol 14:579-85.
3. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. 1995. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 274:1049-57.
4. Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. 1994. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 236:633-41.
5. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. 1998a. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the results of a meta analysis. Circulation 98:2520-26.
6. Brattstrom L, Zhang Y, Hurtig M, Refsum H, Ostensson S, Fransson L, Jones K, Landgren F, Brudin L, Ueland PM. 1998b. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis 141:315-9.
7. de Bree A. 2001. Dietary, lifestyle and genetic determinants of homocysteine and its relation with coronary heart disease. Thesis, Katholieke Universiteit Nijmegen.
8. de Bree A, Verschuren WMM, Blom HJ, Graaf-Hess A, Trijbels FJM, Kromhout D. 2001. The homocysteine distribution: (mis)judging the burden. J Clin Epidemiol 54:462-9.
9. Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. 2001. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost 85:67-74.
10. Dierkes J, Jeckel A, Ambrosch A, Westphal S, Luley C, Boeing H. 2001. Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Potsdam Study. Metabolism 50:640-5.
11. Eliason SC, Ritter D, Chung HD, Creer M. 1999. Interlaboratory variability for total homocysteine analysis in plasma. Clin Chem 45:315-6.
12. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. 1995. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Gent 56:142-50.
13. Fletcher O, Kessling AM. 1998. MTHFR association with arteriosclerotic vascular disease? Hum Genet 103:11-21.
14. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. 2002. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 31:59-70.
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Metthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R. 1995. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-3.
16. Gaustadnes M, Rudiger N, Moller J, Rasmussen K, Larsen TB, Ingerslev J. 1999. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis 10:251-9.
17. Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schnede J, Vollset SE, Refsum H. 1996. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 mmol/1). J Clin Invest 98:2174-83.
18. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. 1997. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 52:495-502.
19. Hak AE, Polderman KH, Westendorp IC, Jakobs C, Hofman A, Witterman JC, Stehouwer CD. 2000. Increased plasma homocysteine after menopause. Atherosclerosis 149:163-8.
20. Homocysteine Lowering Trialists' Collaboration. 1998. Lowering blood homocysteine with folic acid based supplements: meta analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. Br Med J [Clin Res] 316:894-8.
21. Hustad S, Uelamd PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schnede J. 2000. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylene tetra hydrofolate reductase C677T polymorphism. Clin Chem 46:1065-71.
22. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R. 1996. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9.
23. Jacques PF, Rosenberg IH, Rogers G, Selhub J, Bowman BA, Gunter EW, Wright JD, Johnson CL. 1999. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 69:482-9.
24. Jacques PF, Bostom AG, Wilson PWF, Rich S, Rosenberg IH, Selhub J. 2001. Determinants of plasma total homocysteine in the Framingham Offspring Cohort. Am J Clin Nutr 73: 613-21.
25. Jacques PF, Kalmbach R, Bagley PJ, Giuseppina TR, Rogers G, Wilson PWF, Rosenberg IH, Selhub J. 2002. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring Cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 132:283-8.
26. Jorgensen HL, Madsen JS, Saleh MMA, Abrahamsen B, Fenger M, Lauritzen JB. 2002. Association of a common alleic popymorphism (C677T) in the methylene tetrahydrofolate reductase gene with a reduced risk of osteoporotic fractures. A case control study in Danish postmenopausal women. Calcif Tissue Int 71:386-92.
27. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G. 1988. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 43:414-21.
28. Kluijtmans LAJ, Whitehead AS. 1999. Reduced frequency of the thermolabile methylenetetrahydrofolate reductase genotype in the elderly. Atherosclerosis 146:395-7.
29. Lynch M, Walsh B. 1988. Genetics and analysis of quantitative traits. Sunderland, MA: Sinauer Associates, Inc.
30. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C, Willett WC, Selhub J, Hennekens CH, Rozen R. 1997. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 57: 1098-102.
31. Moller J, Christensen L, Rasmussen K. 1997. An external quality assessment study on the analysis of methylmalonic acid and total homocysteine in plasma. Scand J Clin Lab Invest 57: 613-9.
32. Norlund L, Grubb A, Fex G, Leksell H, Nilsson JE, Schenck H, Hultberg B. 1998. The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 36:175-8.
33. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PE, Kvale G. 1995. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274:1526-33.
34. Nygard O, Refsum H, Ueland PM, Vollset SE. 1998. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 67: 263-70.
35. Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. 1999. Total homocysteine and cardiovascular disease. J Intern Med 246:425-54.
36. Ray JG, Laskin CA. 1999. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 20:519-29.
37. Refsum H, Fiskerstrand T, Gutormsen AB, Ueland PM. 1997. Assessment of homocysteine status. J Inherited Metab Dis 20:286-94.
38. Refsum H, Ueland PM, Nygard O, Vollset SE. 1998. Homocysteine and cardiovascular disease. Annu Rev Med 49:31-62.
39. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. 1993. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270: 2693-8.
40. Selhub J, Jacques PF, Rosenberg IH, Rogers G, Bowman BA, Gunter EW, Wright JD, Johnson CL. 1999. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 131:331-8.
41. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino B, Wilson PWF, Wolf PA. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346:476-83.
42. Thomsen TF, Davidsen M, Ibsen H, Jorgensen T, Jensen G, Borch-Johnsen K. 2001. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials: PRECARD® and the Copenhagen risk score. J Cardiovasc Risk 8:291-7.
43. Vollset SE, Refsum H, Tverdal A, Nygard O, Nordrehaug JE, Tell GS, Ueland PM. 2001. Plasma total homocysteine and cardiovascular and non-cardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 74:130-6.
44. Weir BS. 1996. Genetic analysis II. Sunderland, MA: Sinauer Associates, Inc.
45. Wouters MG, Moorrees MT, van der Mooren MJ, Blom HJ, Boers GH, Schellekens LA. 1995. Plasma homocysteine and menopausal status. Eur J Clin Invest 25:801-5.